Male pattern hair loss is among the most treatable conditions in men's health, when addressed early, with the right medications under proper physician oversight. Eros MD provides finasteride, minoxidil, and combination protocols. Discreetly, online.
about male pattern hair loss
Male pattern baldness (androgenetic alopecia) affects approximately 50 percent of men by age 50 and up to 80 percent by age 70. It is the most common form of hair loss in men, and one of the most treatable when addressed in early to middle stages.
The mechanism is driven by DHT (dihydrotestosterone), a potent androgen derived from testosterone. In genetically predisposed men, DHT binds to receptors in hair follicles and causes follicular miniaturization: the gradual shrinking of follicles, producing thinner, shorter hairs until the follicle stops producing hair entirely.
The most important thing to understand about hair loss treatment: the earlier it starts, the better. Finasteride and minoxidil cannot restore follicles that have already fully miniaturized. They work best to preserve what you have and potentially recover recent losses. Acting in the first stages of noticeable thinning produces dramatically better outcomes than waiting.
treatment options
Five clinically validated treatment paths, each prescribed after a licensed physician reviews your intake. No guesswork, no OTC-only half-measures.
The most clinically proven oral hair loss medication. A 5-alpha reductase inhibitor that blocks DHT, the hormonal root cause of male pattern baldness. Clinical studies show it stops hair loss in over 80 percent of men and produces regrowth in approximately 66 percent at two years.
Low-dose oral minoxidil is a rapidly growing physician-prescribed option for men who want a systemic hair loss approach, or have not achieved optimal results with topical minoxidil alone. Increasing clinical evidence supports its effectiveness.
Applied directly to the scalp, topical minoxidil has decades of clinical data. It increases blood flow to follicles and extends the growth phase. Available at standard 5 percent and higher physician-prescribed concentrations.
Clinical evidence consistently shows combination therapy produces better results than either medication alone. Finasteride addresses the hormonal cause; minoxidil stimulates follicular activity through a separate mechanism. Coordinated under one physician's oversight at Eros MD.
Hair thinning in women has different drivers — iron, thyroid, post-partum shifts, perimenopause. Eros MD's women's program is built around female-pattern hair loss, not adapted from a men's protocol.
medication comparison
Finasteride
Minoxidil
Feature
Mechanism
Form
Frequency
Primary Effect
Best For
Finasteride
5-alpha reductase inhibitor (blocks DHT)
Oral tablet
Once daily
Prevents further loss, supports regrowth
Hormonally driven loss
Minoxidil
Vasodilator and growth cycle extender
Oral or topical
Daily (oral) or twice daily (topical)
Stimulates growth, increased density
Pairs effectively with finasteride
results timeline
Hair loss treatment requires patience. Setting realistic expectations upfront prevents patients from abandoning treatment too early, the most common mistake. Visible change is gradual and best tracked with periodic photos.
Most clinical studies measure results at 12 to 24 months of consistent use. Treatment requires continued use. Stopping either finasteride or minoxidil results in gradual return of hair loss within 6 to 12 months.
No visible change expected. Some patients experience initial shedding, which is normal and indicates the medication is working. Hair loss typically begins to slow toward month 4. Take regular photos to track.
Meaningful reduction in hair loss for most patients. Early regrowth possible at the crown for men on combination therapy. Full assessment of treatment efficacy at 12 months.
Maximum regrowth benefit typically at 12 to 18 months. Treatment requires ongoing use. Stopping returns you to baseline progression over 6 to 12 months.
Questions worth asking
Clinical evidence consistently shows that combination therapy, finasteride plus minoxidil, produces the best results for male pattern baldness. Finasteride addresses the hormonal cause (DHT). Minoxidil stimulates follicular activity through a separate mechanism. Used together under physician supervision, they produce significantly better outcomes than either alone.
Yes. Finasteride is FDA-approved for male pattern hair loss and is the most clinically validated oral option available. Studies show it prevents further hair loss in over 80 percent of men after two years, and promotes regrowth in approximately 66 percent. Most effective when started early in the hair loss process.
Most patients begin to see results, reduced shedding and early regrowth, at 3 to 6 months. Full assessment of efficacy requires 12 months of consistent treatment. Hair loss medications require ongoing use. Stopping results in return of hair loss.
Finasteride has a well-established safety profile from decades of clinical use. Sexual side effects (reduced libido, changes in erection quality) are reported in approximately 1 to 4 percent of patients in clinical studies, typically reversible upon discontinuation. Your Eros MD provider reviews health history and risk profile before prescribing.
Yes, and clinical evidence suggests the combination is more effective than either alone. Eros MD's combination protocol coordinates both under physician oversight. No known significant interactions between finasteride and minoxidil.
learn more
Clear, physician-reviewed explainers on how hair loss treatments work, what to expect, and how to decide between the options available to you.
Mechanism, efficacy, and practical considerations for choosing between 5-alpha reductase inhibitors.
What the clinical evidence actually shows about minoxidil efficacy, and why expectations matter for how you evaluate your response.
A side-by-side look at adherence, absorption, efficacy, and side-effect profiles for oral and topical minoxidil.
Finasteride blocks the hormonal driver. Minoxidil stimulates the follicular cycle. Combining them targets both mechanisms, and the data shows it matters.